View More


View More

Welcome to RamanPharma!

Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.

Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.

Our UK and Ireland Products

The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.

They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.


Pharmacy News
  • Promoting pharmacy to MPs: PSNC and others to host roundtable events
    Friday, September 20, 2019 5:14 pm

    Over the next fortnight PSNC and the other national community pharmacy representative bodies will be making the case for pharmacy at both the Labour and Conservative Party Conferences. PSNC, the Association of Independent Multiple Pharmacies (AIM), the Company Chemists’ Association (CCA) and the National Pharmacy Association (NPA) are jointly hosting roundtable events at both conferences...

  • Brexit: Important update for pharmacies
    Friday, September 20, 2019 5:09 pm

    As we head towards the UK’s planned exit from the European Union, the Government’s guidance and messaging for the public and those involved in the medicines supply chain has evolved. Below is a round-up of recent events that community pharmacy teams need to be aware of. Patient messaging revised The patient information about a no-deal...

  • September 2019 Price Concessions – 1st update
    Friday, September 20, 2019 3:00 pm

    Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price concession Betahistine 8mg tablets 84 £1.65 Betahistine 16mg tablets 84 £2.99 Co-careldopa 12.5mg/50mg tablets 90 £10.73 Cyclizine 50mg/1ml solution for injection ampoules 5 £14.00 Escitalopram 10mg tablets 28 £3.19 Ibandronic acid 150mg tablets 1...

  • Shortage Notice: Fluoxetine 10mg, 30mg and 40mg capsules
    Friday, September 20, 2019 2:26 pm

    Morningside and Advanz, the manufacturers of Fluoxetine 10mg, 30mg and 40mg capsules, are currently experiencing temporary disruptions. Please see a table below which summarises the overall fluoxetine availability: Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘Special Order’ and...

  • CPCS Toolkit published
    Friday, September 20, 2019 2:10 pm

    The NHS Community Pharmacist Consultation Service (CPCS) will commence on 29th October 2019 and the Toolkit to support pharmacy teams to provide the service has just been published on the NHSBSA website. The Toolkit has been developed by NHS England and NHS Improvement (NHSE&I), with input from the Urgent Care Delivery and Implementation Group (a group of...

  • Shortage Notice: Provera (medroxyprogesterone acetate) 100mg tablets
    Friday, September 20, 2019 1:50 pm

    Pfizer, the sole supplier of Provera tablets, are experiencing manufacturing delays, and are out of stock of the 100mg tablets until week ending 8th November 2019. Provera 200mg and 400mg tablets remain available, but Pfizer say ‘they are unable to bridge the gap without going out of stock’. For guidance on alternative agents and management...

  • Contractor notice: Clarification on dental prescription reimbursement
    Friday, September 20, 2019 1:08 pm

    It has come to PSNC’s attention that inaccurate information has been circulating about the processing and reimbursement of dental prescriptions (FP10D) with stamped drug information. Some pharmacy teams have reported that they had heard that the NHS Business Service Authority (NHSBSA) ignores handwritten quantities on stamped prescriptions unless the quantity specified is initialled or countersigned...

  • MPs investigate prescription exemption and penalty charge notice system
    Friday, September 20, 2019 10:15 am

    The Public Accounts Committee (PAC) has today published a report of its investigation into penalty charge notices in healthcare, calling for an overhaul of the system which it considers “not fit for purpose”. The PAC is made up of a group of cross-party MPs; the Committee launched an inquiry after it became concerned that penalty...

  • Resources available to assist with meeting the diabetes quality criterion from 1st October
    Thursday, September 19, 2019 2:52 pm

    PSNC has published Briefing 043/19: Pharmacy Quality Scheme – Foot and eye screening (retinopathy) checks for patients with diabetes to assist community pharmacy contractors with getting ready to meet the diabetes quality criterion of the Pharmacy Quality Scheme (PQS), which contractors need to start working towards from 1st October 2019. The Briefing explains how to...

  • MHRA Drug Safety Update September 2019
    Thursday, September 19, 2019 2:28 pm

    A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 1 August 2019) has been published and includes articles on: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication...

MHRA Regulatory News
VMD Regulatory News
Global Pharmaceutical News


Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF


Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.


- +44 (0)1252 260 460.
- +44 (0)1276 469 290


Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available